Deutsche Bank AG Reiterates “Buy” Rating for Shire PLC (SHP)
Deutsche Bank AG reaffirmed their buy rating on shares of Shire PLC (LON:SHP) in a research report report published on Monday, Marketbeat Ratings reports. They currently have a GBX 5,500 ($72.34) target price on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on the stock. Liberum Capital reaffirmed a buy rating and issued a GBX 4,200 ($55.24) target price on shares of Shire PLC in a research note on Monday. Kepler Capital Markets reaffirmed a buy rating and issued a GBX 4,600 ($60.50) target price on shares of Shire PLC in a research note on Friday, November 17th. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a research note on Friday, November 17th. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a research note on Monday, November 13th. Finally, Berenberg Bank lifted their target price on shares of Shire PLC from GBX 5,900 ($77.60) to GBX 6,000 ($78.92) and gave the stock a buy rating in a research note on Monday, November 6th. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of GBX 5,272.22 ($69.34).
Shares of Shire PLC (SHP) opened at GBX 3,735 ($49.13) on Monday. Shire PLC has a 12 month low of GBX 3,435.50 ($45.19) and a 12 month high of GBX 5,067 ($66.64).
COPYRIGHT VIOLATION NOTICE: “Deutsche Bank AG Reiterates “Buy” Rating for Shire PLC (SHP)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/24/deutsche-bank-ag-reiterates-buy-rating-for-shire-plc-shp.html.
In related news, insider Anne Minto acquired 190 shares of the stock in a transaction dated Friday, September 29th. The stock was bought at an average cost of GBX 3,785 ($49.78) per share, with a total value of £7,191.50 ($9,458.77).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.